Related Experiment Video
Updated: Jul 2, 2026
05:46
Endotracheal Intubation of Rabbits Using a Polypropylene Guide Catheter
Published on: November 13, 2017
33.3K
Effects of Inhaled Dexamethasone/Ciprofloxacin on Acute Subglottic Stenosis in a Rabbit Model
I-Chun Kuo1,2, Catherine K Hart3,4, Isabelle M Gengler4
1Department of Otolaryngology-Head & Neck Surgery Chang Gung Memorial Hospital Taoyuan Taiwan.
Laryngoscope Investigative Otolaryngology
|April 28, 2025
Summary
Inhaled dexamethasone/ciprofloxacin did not prevent subglottic stenosis (SGS) in rabbits. Longer survival times were linked to smaller airway openings, indicating SGS worsens over time.
Area of Science:
- Otolaryngology
- Pulmonology
- Medical Research
Background:
- Subglottic stenosis (SGS) is a significant complication following airway interventions.
- Current evidence for effective preventive strategies for acute SGS is limited.
Purpose of the Study:
- To investigate the potential preventive effects of inhaled dexamethasone/ciprofloxacin on acute subglottic stenosis.
- To evaluate the impact of treatment duration and survival time on SGS development in a rabbit model.
Main Methods:
- New Zealand White rabbits underwent endoscopic subglottic injury.
- Inhalation therapy with dexamethasone/ciprofloxacin or saline was administered for 5 or 10 days.
- Histological analysis of cricoid lumen measurements was performed at various time points.
Main Results:
- No significant difference in cricoid lumen measurements was observed between the treatment and control groups.
- Both 5-day and 10-day treatment durations showed no significant difference in preventing SGS.
- Multivariate analysis revealed that cessation of therapy and prolonged survival were associated with reduced cricoid lumen size.
Conclusions:
- Short-term inhalation therapy with dexamethasone/ciprofloxacin does not prevent acute subglottic stenosis in this rabbit model.
- The study suggests that SGS progression is time-dependent, as longer survival correlated with smaller airway lumens.
Related Concept Videos
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:26Modeling in Therapy
Modeling, a key technique in therapy, uses observational learning to help clients acquire and practice new skills by watching therapists demonstrate desired behaviors. This approach, rooted in Albert Bandura's concept of vicarious learning, plays a significant role in therapeutic interventions for various psychological conditions, including social anxiety, ADHD, and depression.
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in situations...
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in situations...
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...